TABLE: In turbulent week, 2 IPOs price, 6 test waters
This article was originally published in Scrip
While the biotechnology industry continues to debate whether the window for initial public offerings is closing, two drug developers priced IPOs during a US stock trading week shortened by the July 4th holiday and six revealed their plans to become public companies.
You may also be interested in...
Intellia Therapeutics Inc. sold more shares in its initial public offering than originally expected and the CRISPR/Cas9 specialist did so at the top of its proposed price range, proving that investors remain excited about gene editing, but have less enthusiasm for other early-stage therapeutics firms.
Bristol became a major hematology player through its acquisition of Celgene and it has a multi-pronged plan for maintaining its position as generics approach for Revlimid and other key products.
The company will seek US FDA approval after intranasally administered zavegepant passes its second pivotal test in the treatment of migraine attacks, followed by ex-US approvals with partner Pfizer.